gene

SLC7A11

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about SLC7A11: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

1364Connections

3Hypotheses

5Analyses

50Outgoing

50Incoming

1Experiments

13Debates

Summary

SLC7A11 is a gene implicated in neurodegeneration research. Key relationships include: activates, associated with, inhibits. Associated with ALS, Aging, Als. Connected to 649 entities in the SciDEX knowledge graph.

View on Wiki →

No AI portrait yet

🧬 Gene Info

Gene Symbol	SLC7A11
Full Name	Solute Carrier Family 7 Member 11 (xCT)
Chromosome	4q28.3
Protein Type	Transporter
Target Class	Transporter
Function	Small molecule inhibition of cystine/glutamate exchange
Mechanism of Action	Small molecule inhibition of cystine/glutamate exchange
Primary Expression	various brain cell types:
Druggability	Medium (0.55)
Clinical Stage	Approved
Pathways	Akt, Autophagy, Epigenetic, Ferroptosis, Glutathione Biosynthesis
UniProt ID	Q9UPY5
Ensembl ID	ENSG00000155511
GeneCards	SLC7A11
Human Protein Atlas	SLC7A11
Associated Diseases	Als, cancer, Carcinoma
Known Drugs/Compounds	alphaKG, curcumin, CURCUMIN, icariin, kynurenine, NICOTINAMIDE
Interactions	ACETYL-COA, ACSL4, AGING, AKT, ALOX, ALOX12
SciDEX Target	View Target Profile (4 clinical trials)
SciDEX Hypotheses	Microglial xCT/SLC7A11 Selective Inhibition to Red
KG Connections	1363 knowledge graph edges
Databases	GeneCards NCBI Gene HPA STRING

🔮 Predicted Structure: SLC7A11 — AlphaFold Q9UPY5 Click to expand

AI-predicted structure from AlphaFold | Powered by Mol*

Wiki Pages (3)

Knowledge base pages for this entity

Canonical Page

SLC7A11 Gene - xCT Cystine/Glutamate Antiporter

gene · 809 words

→

Validated Hypothesis: SLC7A11 System Activation Restores Cystine Uptake and GSH Synthesis to Prevent Neuronal and Endothelial Ferroptosis After Cardiac Arrest

hypothesis · 4820 words

→

xCT Protein - SLC7A11 Cystine/Glutamate Antiporter

protein · 665 words

→

Pathway Diagram

flowchart TD
    SLC7A11(["SLC7A11"])
    ferroptosis("ferroptosis")
    ROS(["ROS"])
    GPX4(["GPX4"])
    FERROPTOSIS(["FERROPTOSIS"])
    Ferroptosis["Ferroptosis"]
    Cancer["Cancer"]
    Als["Als"]
    Tumor["Tumor"]
    P53(["P53"])
    CANCER(["CANCER"])

    SLC7A11 -.->|"inhibits"| ferroptosis
    SLC7A11 -.->|"inhibits"| ROS
    SLC7A11 -->|"regulates"| GPX4
    SLC7A11 -.->|"inhibits"| FERROPTOSIS
    SLC7A11 -->|"activates"| GPX4
    SLC7A11 -->|"activates"| Ferroptosis
    SLC7A11 -.->|"inhibits"| GPX4
    SLC7A11 -.->|"inhibits"| Ferroptosis
    SLC7A11 -->|"activates"| Cancer
    SLC7A11 -->|"activates"| Als
    SLC7A11 -->|"activates"| Tumor
    SLC7A11 -->|"activates"| P53
    SLC7A11 -->|"activates"| FERROPTOSIS
    SLC7A11 -->|"activates"| CANCER
    SLC7A11 -->|"activates"| ROS

    style SLC7A11 fill:#006494,stroke:#4fc3f7,stroke-width:3px,color:#e0e0e0

Outgoing (780)

Target	Relation	Type	Str
SLC7A11	encodes	protein	0.00
GPX4	regulates	protein	1.00
Ferroptosis	inhibits	pathway	1.00
GPX4	activates	gene	1.00
P53	activates	gene	1.00
GPX4	inhibits	gene	1.00
ferroptosis	inhibits	phenotype	1.00
CANCER	activates	gene	1.00
Als	activates	disease	1.00
FERROPTOSIS	activates	gene	1.00
Cancer	activates	disease	1.00
ROS	inhibits	drug	1.00
FERROPTOSIS	inhibits	phenotype	1.00
Ferroptosis	activates	pathway	1.00
ROS	activates	gene	1.00
Tumor	activates	disease	1.00
Ferroptosis Resistance	mediates	phenotype	0.90
Ferroptosis Suppression	involved_in	process	0.90
Chondrocyte Ferroptosis	inhibits	process	0.90
Cystine Import	mediates	process	0.90
glutamate release	modulates	process	0.90
Liver Inflammation	inhibits	process	0.90
Nonalcoholic Steatohepatitis	protects_against	disease	0.90
Alpha-Ketoglutarate	upregulates	compound	0.90
ferroptosis	participates_in	pathway	0.90
NASH	protects_against	disease	0.90
ROS	downregulates	process	0.90
Liver Fibrosis	protects_against	disease	0.90
oxidative stress response	participates_in	pathway	0.90
unfolded protein response	participates_in	pathway	0.90
Ferroptosis	regulates	pathway	0.90
OXIDATIVE STRESS	inhibits	gene	0.90
Apoptosis	activates	pathway	0.90
NRF2	activates	gene	0.90
APOPTOSIS	activates	gene	0.90
FERROPTOSIS	regulates	gene	0.90
ferroptosis	protects_against	process	0.88
FERROPTOSIS	protects_against	entity	0.88
Glutathione Biosynthesis	regulates	pathway	0.88
Tumor Growth	associated_with	phenotype	0.88
Als	therapeutic_target	disease	0.85
Kynurenine	associated_with	compound	0.85
Hepatic Stellate Cell Ferroptosis	involved_in	process	0.85
Tumor	inhibits	disease	0.85
NASH Progression	protects_against	disease	0.85
Cancer	inhibits	disease	0.85
Neurodegeneration	activates	disease	0.85
Ferroptosis	protects_against	process	0.85
Tumor	therapeutic_target	disease	0.85
Colorectal Cancer	activates	disease	0.85

Incoming (584)

Source	Relation	Type	Str
SLC7A11	encodes	gene	0.00
TMEM16F	regulates	gene	1.00
STAT6	upregulates	gene	0.95
NRF2	upregulates	protein	0.95
FOXK2	upregulates	protein	0.95
GPX4	associated_with	gene	0.90
Klebsiella Pneumoniae	downregulates	disease	0.90
NFE2L2	upregulates	gene	0.90
BECN1	inhibits	protein	0.90
Rotenone	downregulates	compound	0.90
h-7957bb2a	targets	hypothesis	0.90
INTERLEUKIN-1 BETA	downregulates	protein	0.85
Paricalcitol	upregulates	drug	0.85
Klebsiella pneumoniae	downregulates	disease	0.85
SIK1	correlates_with	gene	0.85
FOXO3	binds	protein	0.85
FOXO3	downregulates	protein	0.85
GPX4	treats	gene	0.80
TP53	downregulates	entity	0.80
ACSL4	associated_with	gene	0.80
Nrf2	regulates	protein	0.72
FOXK2	regulates	protein	0.72
JAK2	regulates	protein	0.70
ALOX12	activates	gene	0.70
ischemia-reperfusion injury	inhibits	process	0.70
C-JUN	upregulates	protein	0.70
NRF2	interacts_with	gene	0.70
PI3K	inhibits	gene	0.70
JNK	upregulates	protein	0.70
FERROPTOSIS	associated_with	phenotype	0.70
NRF2 activation	upregulates	pathway	0.70
FERROPTOSIS	causes	phenotype	0.65
FOXO3	interacts_with	gene	0.65
HIF1A	regulates	protein	0.64
STAT6	activates	protein	0.64
paricalcitol	activates	drug	0.64
c_Jun	regulates	protein	0.64
ETV4	regulates	protein	0.64
IL1B	inhibits	gene	0.64
icariin	activates	drug	0.64
OGD_R	inhibits	phenotype	0.64
kynurenine	interacts_with	drug	0.64
ACSL4	expressed_in	gene	0.60
LC3	associated_with	gene	0.60
IDO1	expressed_in	gene	0.60
TFR1	expressed_in	gene	0.60
PI3K	activates	gene	0.60
BMAL1	associated_with	gene	0.60
FOXO3	inhibits	gene	0.60
OGT	activates	gene	0.60

Targeting Hypotheses (3)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
SLC7A11 System Activation Restores Cystine Uptake and GSH Sy	0.812	neurodegeneration	Can ferroptosis inhibitors prevent BBB d
Microglial xCT/SLC7A11 Selective Inhibition to Reduce Non-Ce	0.620	-	Ferroptosis in ALS and motor neuron dise
EP4 Receptor Agonism for SLC7A11 Upregulation	0.550	neurodegeneration	Can ferroptosis inhibitors prevent BBB d

Mentioning Analyses (5)

Scientific analyses that reference this entity

Experiments (1)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
Gandouling protection against brain injury in Wilson's disease via SIR	validation	Hepatolenticular degeneration	0.900	0.00	TX mice (Wilson's disease mode	proposed	N/A

Related Papers (5)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year
Enhancing TREM2 expression activates microglia and modestly mitigates tau pathol [PMID:40122810]	["Chen Kai", "Li Fuyao", "Zhang Shuwen",	Journal of neuroinflammation	2025
Enhancing TREM2 expression activates microglia and modestly mitigates tau pathol [PMID:40122810]	["Chen Kai", "Li Fuyao", "Zhang Shuwen",	Journal of neuroinflammation	2025
Neurodegeneration and Inflammation-An Interesting Interplay in Parkinson's Disea [PMID:33182554]	Marogianni C, Sokratous M, Dardiotis E,	International journal of molec	2020
Neurodegeneration and Inflammation-An Interesting Interplay in Parkinson's Disea [PMID:33182554]	Marogianni C, Sokratous M, Dardiotis E,	International journal of molec	2020
Multiple Sclerosis Pathology. [PMID:29358320]	Lassmann H	Cold Spring Harbor perspective	2018

Debates (13)

Multi-agent debates referencing this entity

Related Research

Hypotheses and analyses mentioning SLC7A11 in their description or question text

No additional research found

SLC7A11

Understanding Entity Pages

Summary

Wiki Pages (3)

SLC7A11 Gene - xCT Cystine/Glutamate Antiporter

Validated Hypothesis: SLC7A11 System Activation Restores Cystine Uptake and GSH Synthesis to Prevent Neuronal and Endothelial Ferroptosis After Cardiac Arrest

xCT Protein - SLC7A11 Cystine/Glutamate Antiporter

Pathway Diagram

Outgoing (780)

Incoming (584)

Targeting Hypotheses (3)

Mentioning Analyses (5)

Can ferroptosis inhibitors prevent BBB disruption and edema formation after card

Ferroptosis in ALS and motor neuron disease: GPX4, lipid peroxidation, and iron

Gene expression changes in aging mouse brain predicting neurodegenerative vulner

Cell type vulnerability in Alzheimers Disease (SEA-AD transcriptomic data)

Senolytic therapy for age-related neurodegeneration

Experiments (1)

Related Papers (5)

Debates (13)

Second debate: Microglial TREM2-SYK Pathway Enhancement

Debate: LPCAT3-Mediated Lands Cycle Remodeling as the Primary Ferroptotic Primin

Debate: ALOX15-Driven Enzymatic Ferroptosis in AD Oligodendrocytes via PUFA-PE P

Debate: LPCAT3-Mediated Lands Cycle Amplification of Ferroptotic Vulnerability i

Debate: ACSL4-Driven Ferroptotic Priming in Disease-Associated Oligodendrocytes

Should '40 Hz Gamma Entrainment Gates ACSL4-Mediated Ferroptotic Priming to Sele

Should 'ACSL4-Ferroptotic Priming in Stressed Oligodendrocytes Drives White Matt

Hypothesis debate: SASP-Mediated Complement Cascade Amplification

Can ferroptosis inhibitors prevent BBB disruption and edema formation after card

Ferroptosis in ALS and motor neuron disease: GPX4, lipid peroxidation, and iron

Related Research